Campaign's response to NICE's announcement on aromatase inhibitors
“Breast Cancer Campaign welcomes today’s announcement from NICE, which shows positive preliminary findings of their review of the use of aromatase inhibitors* for postmenopausal women with early breast cancer.
This is the culmination of research which started 20 years ago and which has indicated that aromatase inhibitors are more effective than tamoxifen.
Campaign hopes to see a positive final decision by NICE for the use of aromatase inhibitors by the NHS in England and Wales in November (bringing the system in line with Scotland which has already approved the use of these treatments). This decision will add to the portfolio of treatments available to clinicians, which could benefit around 23,000 women with breast cancer each year.”
Pamela Goldberg, Chief Executive, Breast Cancer Campaign